MiniMed Group (NASDAQ:MMED) Issues Quarterly Earnings Results

MiniMed Group (NASDAQ:MMED) released its earnings results on Friday. The company reported $999.00 earnings per share for the quarter, Zacks reports.

MiniMed Group Stock Up 3.0%

NASDAQ MMED traded up $0.42 during trading hours on Friday, hitting $14.44. The company had a trading volume of 816,560 shares, compared to its average volume of 1,082,985. MiniMed Group has a fifty-two week low of $12.80 and a fifty-two week high of $20.48.

Analysts Set New Price Targets

A number of equities analysts recently commented on MMED shares. Zacks Research upgraded MiniMed Group to a “hold” rating in a research note on Thursday, April 9th. Bank of America initiated coverage on MiniMed Group in a report on Tuesday, March 31st. They set a “buy” rating and a $27.00 target price on the stock. Morgan Stanley assumed coverage on MiniMed Group in a report on Tuesday, March 31st. They issued an “overweight” rating and a $19.00 price target for the company. Barclays initiated coverage on MiniMed Group in a research note on Wednesday, April 1st. They set an “overweight” rating and a $26.00 price objective on the stock. Finally, Mizuho assumed coverage on shares of MiniMed Group in a research note on Tuesday, March 31st. They set an “outperform” rating and a $21.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, MiniMed Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.45.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.